Trials / Conditions / Allogeneic Hematopoietic Stem Cell Transplantation Recipient

Allogeneic Hematopoietic Stem Cell Transplantation Recipient

10 registered clinical trials studyying Allogeneic Hematopoietic Stem Cell Transplantation Recipient — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Prehabilitation for Patients Diagnosed With Blood Cancer and Treated With Al-logeneic Hematopoietic Stem Cell NCT07341698	Rigshospitalet, Denmark	N/A
Not Yet Recruiting	VIROMARKERS GA n.101194735 - CMV and TTV Biomarkers Study Protocol NCT07286461	University of Rome Tor Vergata	—
Withdrawn	Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ NCT03851081	Roswell Park Cancer Institute	Phase 1 / Phase 2
Recruiting	Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT NCT03665675	Sumithira Vasu	EARLY_Phase 1
Active Not Recruiting	High Dose Vitamin A in Preventing Gastrointestinal GVHD in Participants Undergoing Donor Stem Cell Transplant NCT03719092	Ohio State University Comprehensive Cancer Center	N/A
Completed	Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant NCT03925532	Roswell Park Cancer Institute	Phase 2
Recruiting	Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Bloo NCT03779854	Fred Hutchinson Cancer Center	Phase 2
Completed	Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Re NCT03600155	M.D. Anderson Cancer Center	Phase 1
Completed	Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in R NCT02083250	M.D. Anderson Cancer Center	Phase 1
Terminated	Allogeneic Stem Cell Transplant for CLL NCT01629511	M.D. Anderson Cancer Center	Phase 1 / Phase 2